Remove Medicare Remove Reimbursement Remove Technology
article thumbnail

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

DAIC

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104
article thumbnail

CMS Updates Medicare Coverage for AI-Coronary Plaque Analysis

DAIC

15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). The SCCT HPPC offers tools for administrators to navigate the complex landscape of insurance plans, billing and reimbursement on SCCT website, scct.org.

CMS 52
article thumbnail

AliveCor's Kardia 12L ECG System Receives Category III CPT Codes

DAIC

CPT codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement. KAI 12L is the world's first AI to detect 35 cardiac determinations, including heart attacks, using a reduced leadset.

article thumbnail

CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

DAIC

Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries.

CMS 52
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS for both treatment and control procedures.

CMS 111
article thumbnail

How Interoperability Can Streamline the MIPS Reporting Changes

GEMMS

Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) , the MIPS Program is pivotal in determining Medicare payment adjustments for healthcare practices. What is MIPS? Additionally, the 2024 final rule retains the methodology for measuring scores and achieving points with no notable alterations.

article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.